Availability and buying

where can i get retatrutide

Published May 2, 2026Updated May 3, 2026Medical safety, official-source, and research-reference review

The search answer is not a seller list. Retatrutide is not approved for public use.

Direct answer

The official access path is a Lilly clinical trial if a person qualifies and a relevant study is available. Public buying claims should be treated with caution.

Research context

These references frame the evidence base behind this topic. They are not medical advice, approval, or instructions for using retatrutide outside a clinical trial.

Short source quoteagonist of the GIP, GLP-1, and glucagon receptors

Jastreboff et al., NEJM 2023 retatrutide phase 2 obesity trial

This peer-reviewed phase 2 paper is the anchor for retatrutide mechanism language. It does not make retatrutide approved or publicly available.

Short source quoterandomised, double-blind, placebo and active-controlled

Rosenstock et al., Lancet 2023 retatrutide phase 2 type 2 diabetes trial

The type 2 diabetes phase 2 paper helps separate controlled clinical research from online self-use claims.

Short source quotequality of the prescription drugs sold online

Lim et al., 2022 systematic review of online pharmacies selling prescription drugs

This systematic review supports online-source caution for prescription-drug searches and marketplace claims.

Short source quoteselling counterfeit, adulterated or unapproved drugs

Limbu and Huhmann, 2023 scoping review of illicit online pharmacies

This scoping review supports warnings about illicit online pharmacies and unapproved prescription-drug access.

Short source quotepreparation errors

McCall et al., Expert Opinion on Drug Safety 2026 compounded GLP-1 pharmacovigilance study

This pharmacovigilance study is relevant to compounded GLP-1 safety signals and product-quality concerns.

What to know before acting on this search

Retatrutide is investigational and is not FDA approved for public sale or prescription.
Lilly says retatrutide is legally available only to participants in Lilly clinical trials while safety and efficacy are evaluated.
FDA warns that some products sold as research-use or not-for-human-consumption GLP-1 drugs may be unapproved, unknown-quality, and harmful.
Clinical trial records can help you see what is recruiting, active, or completed.

Safety and compliance notes

A local, online, or international listing is still not FDA approval.
Unapproved products can create medical, legal, and quality risks.
Approved treatment options should be discussed with a licensed healthcare provider.

Safer next step

Use the clinical-trials page for access context and the online seller warning page for listing-risk context.

Medical disclaimer

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. I am not a medical professional. Always consult a qualified healthcare provider before starting, stopping, or changing any weight loss treatment. Individual results vary. Retatrutide is investigational and is not FDA approved. FDA-approved options such as semaglutide and tirzepatide require prescriptions and should only be used under medical supervision.